RNS

RNS Number : 6262V MaxCyte, Inc. 11 August 2022           MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results   45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022   Raises 2022 Core Revenue Growth Guidance to Approximately 30%   ROCKVILLE, MD , August 11, 2022

RNS Number : 6259V MaxCyte, Inc. 11 August 2022           MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022     ROCKVILLE, MD , August 11, 2022  -  MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell-engineering company focused on providing

RNS Number : 6629U MaxCyte, Inc. 02 August 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Rockville, MD - 2 August 2022 :       MaxCyte (LSE: MXCT),   a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

RNS Number : 1318T MaxCyte, Inc. 20 July 2022         Change of Registered Office   GAITHERSBURG, MD , July 20, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based

RNS Number : 6595S MaxCyte, Inc. 15 July 2022   MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022   GAITHERSBURG, MD , July 15, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform

RNS Number : 1712S MaxCyte, Inc. 12 July 2022                                                                   MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs   LG Chem to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to

RNS Number : 0898S MaxCyte, Inc. 12 July 2022     MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options   Gaithersburg, Maryland - 12 July 2022 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), the global clinical-stage cell-based therapies and life sciences company, announces that on 29 June

RNS Number : 9121R MaxCyte, Inc. 08 July 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)   i 1a. Identity of the issuer or the underlying issuer of existing

RNS Number : 9281Q MaxCyte, Inc. 01 July 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 July 2022 :       MaxCyte (LSE: MXCT),   a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

RNS Number : 7279Q MaxCyte, Inc. 30 June 2022         Result of AGM   GAITHERSBURG, MD , June 30, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as